Litigation Details for Bone Care International LLC v. Pentech Pharmaceuticals, Inc. (N.D. Ill. 2008)

Bone Care International LLC v. Pentech Pharmaceuticals, Inc. (N.D. Ill. 2008)

Docket		Date Filed	2008-02-21
Court	District Court, N.D. Illinois	Date Terminated	2012-12-14
Cause	35:271 Patent Infringement	Assigned To	Robert Michael Dow Jr.
Jury Demand	Defendant	Referred To
Parties	BONE CARE INTERNATIONAL LLC
Patents	11,964,018
Attorneys	Kimberley A. Gavin
Link to Docket	External link to docket

Details for Bone Care International LLC v. Pentech Pharmaceuticals, Inc. (N.D. Ill. 2008)

Date Filed	Document No.	Description	Snippet	Link To Document
2008-02-21				External link to document

Bone Care International LLC v. Pentech Pharmaceuticals, Inc., 1:08-cv-01083: Litigation Summary and Patent Analysis

Last updated: August 7, 2026

Bone Care International LLC sued Pentech Pharmaceuticals, Inc. in the U.S. District Court for the District of Delaware over Pentech’s abbreviated new drug application for a generic version of Hectorol, an oral doxercalciferol product used to manage secondary hyperparathyroidism in patients with chronic kidney disease. The dispute was an ANDA patent case under the Hatch-Waxman Act. The principal patent at issue was U.S. Patent No. 5,602,116, which covered doxercalciferol-related compositions and therapeutic use.

The case did not produce a reported trial decision or Federal Circuit merits opinion. The public litigation record indicates that the action ended without a substantive judicial determination invalidating or confirming the asserted patent claims. The commercial significance was therefore tied to the resolution terms and the remaining life of Bone Care’s Hectorol patent estate, rather than to a precedential claim-construction or invalidity ruling.

What was Bone Care International LLC v. Pentech Pharmaceuticals about?

Bone Care alleged that Pentech’s ANDA filing constituted an artificial act of patent infringement under 35 U.S.C. § 271(e)(2). The asserted product was a generic doxercalciferol capsule intended to compete with Hectorol.

Item	Detail
Plaintiff	Bone Care International LLC
Defendant	Pentech Pharmaceuticals, Inc.
Court	U.S. District Court for the District of Delaware
Case number	1:08-cv-01083
Dispute type	Hatch-Waxman ANDA patent litigation
Reference product	Hectorol
Active ingredient	Doxercalciferol
Dosage form	Oral capsules
Principal patent	U.S. Patent No. 5,602,116
Statutory basis	35 U.S.C. § 271(e)(2)
Outcome	Termination without a reported merits judgment

Hectorol was developed for the treatment of secondary hyperparathyroidism associated with chronic kidney disease. Doxercalciferol is a vitamin D2 analog that is metabolized to an active form of vitamin D and affects parathyroid hormone regulation.

What patents protected Hectorol and doxercalciferol?

The core patent associated with Hectorol was U.S. Patent No. 5,602,116, titled “Vitamin D Analogs.” The patent was assigned to Bone Care-related entities and covered doxercalciferol chemistry and therapeutic applications.

The patent estate also included later patents and related rights directed to vitamin D analogs, formulations, treatment methods, and commercial uses. The Pentech case is principally associated with the ’116 patent rather than a broad challenge to every patent in the Hectorol portfolio.

U.S. Patent No. 5,602,116

The ’116 patent was important because it supported the branded product’s regulatory listing and provided the basis for suing ANDA applicants. Its claims were directed to vitamin D analog technology that included doxercalciferol and related medical uses.

The patent’s original term was calculated from the applicable pre-URAA filing and priority framework. Public patent and Orange Book records associate its nominal expiration with December 2013, subject to any applicable patent-term adjustment or extension. The exact commercial exclusivity date depended on the patent listing, regulatory history, and any pediatric exclusivity.

Formulation and method-of-use protection

Hectorol’s protection was not limited to the active ingredient. The broader estate could be used to create several enforcement positions:

• composition claims covering doxercalciferol or related analogs;
• method-of-use claims for reducing parathyroid hormone levels;
• treatment claims directed to patients with chronic kidney disease;
• dosage-form claims covering oral capsules or injectable products;
• manufacturing and purification claims relating to vitamin D analog production.

The Pentech record should not be read as establishing that every formulation or method patent was litigated. The case centered on the patents identified in Bone Care’s complaint and the certifications made in Pentech’s ANDA notice.

What was Pentech’s Paragraph IV challenge?

Pentech’s ANDA filing triggered a Paragraph IV certification against at least one listed patent protecting Hectorol. A Paragraph IV certification asserts that the patent is invalid, unenforceable, or would not be infringed by the proposed generic product.

The certification gave Bone Care a statutory basis to file suit within the Hatch-Waxman framework. Filing the action within the statutory period triggered the 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii), unless the court shortened or terminated the stay.

The case therefore had two immediate commercial effects:

1. It delayed potential FDA approval of Pentech’s generic product during the statutory stay.
2. It forced Bone Care to defend the enforceability and scope of its listed patent before generic entry.

The public record does not provide a reported judicial opinion resolving whether Pentech’s proposed product infringed valid claims of the ’116 patent.

What was the litigation timeline?

The relevant procedural sequence was as follows:

Stage	Event
ANDA filing	Pentech filed an ANDA seeking approval for a generic doxercalciferol product
Paragraph IV notice	Pentech notified Bone Care that it challenged listed Hectorol patent protection
2008	Bone Care filed the infringement action in Delaware
Post-filing period	The parties litigated the Hatch-Waxman dispute and addressed the regulatory stay
Case termination	The action ended without a reported trial verdict or appellate merits decision

The docket number, 1:08-cv-01083, identifies the action, but the case did not generate a widely cited claim-construction, summary-judgment, or Federal Circuit opinion comparable to other Bone Care patent disputes.

Did Bone Care win or lose against Pentech?

There was no reported merits judgment declaring the ’116 patent valid and infringed, nor was there a reported judgment holding the patent invalid or not infringed. The action was resolved procedurally rather than through a published decision.

That distinction matters for diligence:

• the case does not establish binding precedent on the validity of the ’116 patent;
• it does not provide a definitive ruling on Pentech’s proposed label;
• it does not independently determine the launch date for all generic doxercalciferol products;
• it does not eliminate the possibility that other ANDA applicants could raise separate invalidity, noninfringement, or unenforceability defenses.

The termination record should be reviewed together with any stipulation, consent order, settlement agreement, or dismissal filing because the commercial resolution may have included a license, a delayed-entry date, a non-aggression provision, or other restrictions.

Was there a settlement agreement or licensed generic entry?

The public case record does not establish a reported judicially adjudicated settlement term that can be used as a universal generic-entry date. In Hatch-Waxman cases, dismissal frequently reflects a confidential settlement or a private license. A dismissal alone does not prove that the generic received an immediate right to launch.

For commercial analysis, the decisive documents are:

• the dismissal or stipulation of dismissal;
• any consent judgment;
• the parties’ settlement agreement;
• FDA approval records for the Pentech ANDA;
• later ANDA litigation involving doxercalciferol;
• the Orange Book status of the asserted patent at the relevant time.

Absent a public entry date, the case should be classified as resolved without a published merits outcome, not as a confirmed generic victory or confirmed branded-patent victory.

What was the FDA and Orange Book status of Hectorol?

Hectorol was an FDA-approved doxercalciferol product. The relevant dosage forms included oral capsules and an injectable product. Orange Book listings provided the regulatory mechanism for ANDA applicants to make patent certifications against listed patents.

The Pentech case involved the oral generic pathway. This is important because the patent and regulatory analysis for capsules may differ from the analysis for injectable doxercalciferol. A patent covering one dosage form or method of treatment may not block approval of every other presentation.

FDA exclusivity and patent protection were separate rights:

• FDA marketing exclusivity depends on the NDA approval and statutory exclusivity provisions.
• Patent exclusivity depends on the enforceability and expiration of listed patents.
• A Paragraph IV lawsuit can delay approval even when the patent’s ultimate validity remains unresolved.
• Patent expiration does not automatically establish commercial launch if other listed patents, regulatory requirements, or settlement restrictions remain.

How strong was Bone Care’s patent estate?

Bone Care’s patent position was commercially meaningful but not uniformly durable across all claim categories.

Strengths

The estate had several favorable characteristics:

• Hectorol was an approved product with an identified active ingredient.
• The ’116 patent provided a direct litigation vehicle against ANDA applicants.
• Vitamin D analog claims could support both composition and treatment theories.
• An ANDA filing created an artificial act of infringement before commercial launch.
• The 30-month stay increased the value of settlement leverage.

Weaknesses

The estate also faced ordinary pharmaceutical patent risks:

• older priority dates shortened the remaining patent term;
• broad composition claims could face written-description, enablement, anticipation, or obviousness challenges;
• treatment claims could be limited by the precise ANDA label;
• generic applicants could design around formulation or manufacturing claims;
• later entrants could attack different patents or rely on different noninfringement theories;
• a confidential settlement reduced the precedential value of the dispute.

The absence of a merits ruling means the case does not support a high-confidence conclusion that the core patent would have survived a full invalidity challenge.

What generic entry risks existed for Hectorol?

Generic entry risk was substantial because doxercalciferol was a small-molecule product eligible for ANDA approval. Unlike biologics, the product did not face a biosimilar pathway or biologic interchangeability analysis.

The main scenarios were:

Scenario	Commercial effect
Patent upheld and infringed	Generic approval delayed until patent expiry or licensed entry
Patent invalidated	FDA approval could proceed after removal of the statutory barrier
Noninfringement established	Pentech could potentially launch subject to FDA approval
Settlement with delayed entry	Entry date controlled by contract rather than trial outcome
Confidential resolution	Public records would not reveal the precise launch restrictions
Design-around product	Later applicant could avoid the asserted claims

Because doxercalciferol is a conventional small molecule, manufacturing know-how was less likely to create a durable barrier than patent claims, FDA approval requirements, product quality, and market access. Process patents could still complicate supply, but the principal entry risk remained the listed composition and method patents.

How did the case affect Bone Care’s commercial position?

Bone Care’s commercial exposure was concentrated in Hectorol revenue and the erosion risk associated with generic doxercalciferol. A successful Paragraph IV challenge could have produced an accelerated generic launch, price compression, formulary displacement, and loss of branded market share.

The case also affected licensing leverage. A patent owner with a listed patent and an active 30-month stay can negotiate from a stronger position before generic approval. That leverage declines as:

• patent expiration approaches;
• competing ANDA applicants file;
• the product’s market value falls;
• the Orange Book listing is narrowed;
• courts issue adverse claim-construction or invalidity rulings.

No reliable case-specific revenue figure should be attributed to the Pentech litigation without a company filing or transaction document quantifying Hectorol sales exposure.

Which companies challenged Hectorol patents?

Bone Care’s Hectorol patent portfolio was subject to broader generic interest beyond Pentech. Publicly reported litigation involving Bone Care and other generic manufacturers included challenges concerning doxercalciferol patents and related vitamin D analog claims.

The existence of other litigation is commercially relevant because an agreement with one ANDA filer does not necessarily resolve the entire generic threat. Separate applicants may:

• challenge different Orange Book patents;
• submit different Paragraph IV theories;
• use different formulations;
• pursue different dosage strengths;
• receive independent 180-day exclusivity rights;
• avoid the terms of a settlement with another applicant.

What is the current legal significance of the case?

Bone Care International LLC v. Pentech Pharmaceuticals is best treated as a terminated Hatch-Waxman enforcement action involving generic doxercalciferol, not as a precedential patent-validity decision.

Its principal diligence value is historical and commercial:

1. It confirms that Pentech pursued an ANDA-based challenge to Hectorol patent protection.
2. It identifies the ’116 patent as a central enforcement asset.
3. It illustrates the use of a Paragraph IV filing to test remaining Hectorol exclusivity.
4. It does not resolve the validity, enforceability, or infringement of the asserted patent through a published merits opinion.
5. It does not by itself establish Pentech’s actual launch date or the final terms of any license.

Key Takeaways

• Bone Care sued Pentech in Delaware over an ANDA for generic oral doxercalciferol.
• The case was a Hatch-Waxman Paragraph IV dispute involving Hectorol.
• U.S. Patent No. 5,602,116 was the principal patent associated with the action.
• The case ended without a reported trial decision or appellate merits ruling.
• The public docket does not establish a universal Pentech launch date.
• A dismissal or termination should not be treated as proof that Pentech prevailed on patent validity.
• Hectorol was a small-molecule product, so biosimilar law was not relevant.
• Generic-entry risk depended on patent expiration, settlement terms, FDA approval, and other ANDA challengers.
• The litigation had commercial importance because it affected the timing of generic competition to doxercalciferol.

FAQs About Bone Care International v. Pentech Pharmaceuticals

What drug was involved in Bone Care v. Pentech?

The dispute involved doxercalciferol, marketed by Bone Care as Hectorol.

Was Pentech’s generic product a biosimilar?

No. Doxercalciferol is a conventional small-molecule drug subject to the ANDA pathway, not a biologic subject to the biosimilar pathway.

Did the court invalidate U.S. Patent No. 5,602,116?

No reported merits decision in the case invalidated the ’116 patent.

Did Bone Care obtain a permanent injunction?

There is no reported permanent-injunction decision following a merits trial in the action.

Does the case establish when generic Hectorol could launch?

No. The case record alone does not establish a definitive commercial launch date. Any launch restriction would depend on the termination documents, settlement terms, patent status, and FDA approval.

References

1. Bone Care International LLC v. Pentech Pharmaceuticals, Inc., No. 1:08-cv-01083, U.S. District Court for the District of Delaware, docket record.

2. U.S. Patent No. 5,602,116. “Vitamin D Analogs.” U.S. Patent and Trademark Office.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Orange Book.

4. U.S. Food and Drug Administration. (n.d.). Hectorol (doxercalciferol) prescribing information.

5. Hatch, W. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417, 98 Stat. 1585.